Prostate biopsy in patients with long-term use of indwelling bladder catheter: What is the rationale?


Autoria(s): Antunes, Alberto A.; Barbosa, Joao Arthur B. A.; Reis, Sabrina T.; Guariero, Mary S.; Fukushima, Julia T.; Dall'Oglio, Marcos F.; Freire, Geraldo de C.; Lucon, Antonio M.; Leite, Katia R.; Srougi, Miguel
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

24/09/2013

24/09/2013

2012

Resumo

Objective: Acute urinary retention (AUR) is expected to occur in 2% to 39% men with benign prostatic hyperplasia. To date, no study has elucidated the effect of long-term use of indwelling bladder catheter on serum prostate specific antigen (PSA) levels and on the incidence of prostate cancer (CaP). The aim of the present study is to analyze the incidence of CaP in patients with long-term use of indwelling bladder catheter and determine some practice patterns on this issue. Materials and methods: The study comprised a retrospective analysis of data from 1,651 patients who had undergone transrectal ultrasound (TRUS)-guided prostate biopsy from July 2004 to June 2009. Among these patients, 198 (12%) were using an indwelling bladder catheter during the biopsy for at least 1 month. The incidence of CaP was recorded according to total PSA levels. Other variables such patient age, free/total PSA rate, PSA density, prostate volume, and duration of catheter use was also analyzed. Men with a digital rectal examination suspicious for cancer were not considered for analysis. Results: Median patient age was 71 years (37 to 89 years). Overall, 25% of patients presented a CaP diagnosis. CaP incidence according to the PSA levels was 0%, 18.9%, 24.5%, and 40.6% for patients with PSA <= 4.0, 4.1-10.0, 10.1-20.0, and >20.0 ng/ml, respectively. When prostate volume was analyzed together, we demonstrated that only 1 (2.4%) patient with PSA below 10.0 ng/ml and prostate volume >60 g had CaP. Median total PSA, PSA density, and prostate volume were statistically different between patients with and without CaP. Conclusions: Prostate biopsy should not be indicated for all patients with diagnosis of BPH and AUR who present an elevated PSA level. Patients with PSA below 10.0 ng/ml, and prostate volume >60 g should only undergo biopsy in selected cases. Patients with PSA >20.0 ng/ml and a prostate volume <= 60 g are at higher risk of CaP diagnosis. (C) 2012 Elsevier Inc. All rights reserved.

Identificador

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, NEW YORK, v. 30, n. 5, pp. 620-623, SEP-OCT, 2012

1078-1439

http://www.producao.usp.br/handle/BDPI/33665

10.1016/j.urolonc.2010.07.013

http://dx.doi.org/10.1016/j.urolonc.2010.07.013

Idioma(s)

eng

Publicador

ELSEVIER SCIENCE INC

NEW YORK

Relação

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Direitos

closedAccess

Copyright ELSEVIER SCIENCE INC

Palavras-Chave #PROSTATE CANCER #DIAGNOSIS #BIOPSY #INDWELLING BLADDER CATHETER #ACUTE URINARY RETENTION #ANTIGEN LEVEL #INFLAMMATION #HYPERPLASIA #CANCER #SERUM #MEN #PSA #ONCOLOGY #UROLOGY & NEPHROLOGY
Tipo

article

original article

publishedVersion